Drug Profile
Research programme: hydroxysteroid dehydrogenase inhibitors - Amgen
Alternative Names: 11β-HSD1 inhibitors - AmgenLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Biovitrum
- Developer Amgen
- Class Benzonitrile; Small molecules; Thiazoles
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Sweden (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)
- 22 Feb 2010 Preclinical development is ongoing in Sweden and USA